Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
about
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaThe influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients.A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.Age and aging in blood disorders: multiple myeloma.Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
P2860
Q36381306-52E615F4-28C7-4950-8038-C54275770343Q37216472-A2646330-2BB0-4EA7-B002-A16B4BC28F32Q37384918-E286FBE7-F0B8-4A1C-A8D3-93A31FAA9CD7Q38807562-EC51D466-4E0D-433C-9932-1AD30C550F6CQ38947433-F1406B4E-EBB9-4540-B194-46DEF2D65C95Q40716636-4B844B39-43B3-4C1D-A1E4-95178D0BBF7EQ41042198-89921F26-F571-4C40-B1B3-ED53370EE99FQ42716199-F51713CA-F510-4069-A9F9-76294141AE47Q48234027-9F1A8972-C765-4895-B3F8-278AFCE36E0EQ52577558-68EC3021-1DE9-4D01-8331-603771A0E6AFQ53544915-86D58AC4-26ED-4F43-B336-2A14DEBCA3EAQ58795876-67833ACD-1E08-456F-AE8A-AD487793C18D
P2860
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Improved survival in myeloma p ...... d a matched normal population.
@en
Improved survival in myeloma p ...... d a matched normal population.
@nl
type
label
Improved survival in myeloma p ...... d a matched normal population.
@en
Improved survival in myeloma p ...... d a matched normal population.
@nl
prefLabel
Improved survival in myeloma p ...... d a matched normal population.
@en
Improved survival in myeloma p ...... d a matched normal population.
@nl
P2093
P2860
P50
P356
P1476
Improved survival in myeloma p ...... nd a matched normal population
@en
P2093
Agneta Swedin
Anders Aldrin
Astrid Gruber
Birgitta Lauri
Cecilie Blimark
Gösta Gahrton
Helene Haglöf Kviele
Johan Aschan
Johan Liwing
Johan Lund
P2860
P304
P356
10.1111/BJH.12685
P407
P577
2013-12-09T00:00:00Z